alemtuzumab
Sign in to saveAlso known as Campath-1H, Campath, Campath Mabcampath, Lemtrada, LDP-03
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477317070
- Drug.type
- mab
- Drug.image
- Alemtuzumab Fab 1CE1.png
- Drug.mab_type
- mab
- Drug.source
- zu/a
- Drug.target
- CD52
- Drug.tradename
- Campath, Mabcampath, Lemtrada, others
- Drug.MedlinePlus
- a608053
- Drug.DailyMedID
- Alemtuzumab
- Drug.pregnancy_AU
- B3
- Drug.pregnancy_AU_comment
- (Lemtrada); B2 (Mabcampath)
- Drug.routes_of_administration
- Intravenous infusion
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG06
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2001
- Admin. routes
- parenteral
- Indications
- acute graft vs. host disease, chronic lymphocytic leukemia, acute lymphoblastic leukemia, unspecified peripheral T-cell lymphoma
via ChEMBL · EBI
Research
3,947 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Mass
- 145453.8
- Has use
- medication
Show 8 more facts
- medical condition treated
- mycosis fungoides
- World Health Organisation international non-proprietary name
- alemtuzumab
- defined daily dose
- 0.13
- subject has role
- monoclonal antibody
- Commons category
- Alemtuzumab
- chemical formula
- C₆₄₆₈H₁₀₀₆₆N₁₇₃₂O₂₀₀₅S₄₀
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~8 min read
Encyclopedic overview
15 sectionsContents
- Medical uses
- Chronic lymphocytic leukemia
- Multiple sclerosis
- Contraindications
- Adverse effects
- Biochemical properties
- History
- Society and culture
- Economics
- Names
- Research
- Antiviral properties
- Graft-versus-host disease
- References
- External links
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.
It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.
Excerpted from Wikipedia’s “alemtuzumab” article, available under the CC BY-SA 4.0 licence.